{"analyses":[{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","estimateComment":"Reference level = TAS x 8 weeks","groupDescription":"Protocol definition","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.74","paramType":"Hazard Ratio (HR)","paramValue":"1.02","statisticalComment":"2-sided significance level = 0.05","statisticalMethod":"Gray's test"},{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","estimateComment":"Reference level = TAS x 8 weeks","groupDescription":"Phoenix definition","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.77","paramType":"Hazard Ratio (HR)","paramValue":"0.97","statisticalComment":"2-sided significance level = 0.05","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52","upperLimit":"59","value":"56"},{"groupId":"OG001","lowerLimit":"56","upperLimit":"63","value":"59"}]}],"title":"Protocol definition"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23","upperLimit":"30","value":"27"},{"groupId":"OG001","lowerLimit":"23","upperLimit":"30","value":"27"}]}],"title":"Phoenix definition"}],"denoms":[{"counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"737"}],"units":"Participants"}],"description":"Protocol definition: Time to BF measured from date of randomization to first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored.\n\nPhoenix definition: Time to BF measured from date of randomization to first of (1) the date of documented rise of 2 ng/ml above the post-treatment(RT end date) nadir or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored. For both definitions BF is estimated using the cumulative incidence method. Ten year rates reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG000","title":"TAS x 8 Weeks"},{"description":"TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG001","title":"TAS x 28 Weeks"}],"paramType":"NUMBER","populationDescription":"Eligible patients with follow-up data","reportingStatus":"POSTED","timeFrame":"From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)","title":"Time to First Biochemical Failure (BF) (10-year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}